感染性腸炎治療市場規模、佔有率和成長分析：按療法、病原體、藥物類別、給藥途徑、最終用戶、患者群體和地區分類－2026-2033年產業預測

2024 年全球傳染性腸胃炎治療市場價值為 5.244 億美元，預計到 2033 年將從 2025 年的 5.5744 億美元成長到 9.0879 億美元，預測期（2026-2033 年）的複合年成長率為 6.3%。

全球感染性腸炎治療市場主要集中在銷售針對各種病原體引起的急性腸炎的治療藥物。沙門氏菌和輪狀病毒等病原體爆發導致的高發病率和高昂的醫療成本，尤其是在低收入地區和免疫力缺乏的人群中，凸顯了該市場的重要性。該市場經歷了顯著的發展演變，最初由口服補液鹽和抗生素推動，隨後益生菌和單株抗體進一步發展。旅行相關感染和食源性感染疾病的增加進一步刺激了市場對有效治療藥物的需求。此外，感染疾病的激增也促使抗病毒和噬菌體療法領域需要快速的技術創新，這為生物技術公司創造了盈利的機會。提高診斷能力對於確保合理使用抗生素、促進標靶治療以及透過全球合作加速臨床開發至關重要。

全球傳染性腸炎治療市場促進因素

全球感染性腸炎治療市場正受到快速床邊診斷試劑盒湧現的顯著推動。這些試劑盒使臨床醫生能夠高效識別感染性腸炎病例並迅速啟動針對性治療。由於這些創新工具能夠延緩疾病進展、縮短住院時間並改善患者整體預後，因此正被醫療專業人員廣泛採用。此外，這些診斷解決方案有助於門診治療，並擴大了可在診斷後立即使用的藥物的市場潛力。隨著床邊檢測的普及，各種醫療機構的需求將會受到刺激，從而促進診斷公司和製藥公司之間的合作，並加速整合治療方案的發展。

全球傳染性腸炎治療市場面臨的限制因素

全球感染性腸炎治療市場面臨嚴峻挑戰，這主要歸因於嚴格的監管要求，這些要求規定新療法必須提供嚴格的安全性和有效性證明。這可能導致研發週期延長，並增加申辦者的財務風險。全面的臨床試驗（通常需要涵蓋不同的患者群體和複雜的終點指標）可能會延遲產品核准，並限制市場准入。因此，製造商往往優先考慮監管路徑更清晰的適應症，這可能會阻礙腸炎創新療法的推出，並抑制整體市場成長。此外，不斷變化的國際標準可能需要在不同地區提交多份申請，這將進一步增加成本，並可能抑制對特定治療領域的投資。

全球傳染性腸炎治療市場趨勢

在全球感染性腸炎治療市場正經歷著向精準微生物組療法的重大轉型，而微生物組科學的進步正是推動這項轉型的重要動力。這種創新方法專注於針對引起腸炎的特定致病菌株，並利用全面的腸內菌叢定序來開發個人化的益生菌和噬菌體療法。透過選擇性地清除有害微生物並保留有益的腸道菌群，這些療法能夠提高治療效果、降低復發率並促進整體腸道健康。這一趨勢將重新定義我們的治療方式，並基於臨床檢驗的方案建立新的標準，為急性和慢性腸道感染疾病提供個人化的解決方案。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 疾病流行病學

全球傳染性腸炎治療市場規模：依治療類型分類

• 抗菌療法
• 抗病毒治療
• 抗寄生蟲治療
• 口服補液療法
• 支持性護理

全球傳染性腸炎治療市場規模：依病原體類型分類

• 細菌性腸炎
• 病毒性腸胃炎
• 寄生蟲性腸炎

全球傳染性腸炎治療市場規模：依藥物類別分類

• 抗生素
• 抗病毒藥物
• 抗寄生蟲藥物
• 止瀉藥
• 益生菌
• 其他

全球傳染性腸炎治療藥物市場規模：依給藥途徑分類

• 口服
• 靜脈

全球傳染性腸胃炎治療市場規模：依最終用戶分類

• 醫院
• 診所
• 門診部
• 居家照護環境

全球傳染性腸炎治療市場規模：依病患小組分類

• 兒童
• 成人
• 老年人

全球傳染性腸胃炎治療市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Sanofi SA
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• GSK plc
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Norgine BV
• Cosmo Pharmaceuticals NV
• RedHill Biopharma Ltd.
• Biocodex SA
• Otsuka Holdings Co., Ltd.
• Dr. Reddy's Laboratories Limited
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Lupin Limited
• Ferring Pharmaceuticals A/S

結論與建議

Global Infectious Enteritis Treatment Market size was valued at USD 524.40 Million in 2024 and is poised to grow from USD 557.44 Million in 2025 to USD 908.79 Million by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global infectious enteritis treatment market focuses on the sales of therapeutic agents for acute intestinal inflammation caused by various pathogens. The significance of this market is underscored by the substantial morbidity and healthcare costs linked to outbreaks of pathogens like salmonella and rotavirus, especially in low-income areas and among immunocompromised individuals. The market has evolved notably, initially driven by oral rehydration solutions and antibiotics, and subsequently enhanced by probiotics and monoclonal antibodies. Increasing travel-related and foodborne infections further fuel market demand for effective treatment options. Additionally, the surge in outbreaks necessitates rapid innovation in antiviral and bacteriophage therapies, creating lucrative opportunities for biotech firms. Enhanced diagnostic capabilities are vital for ensuring proper antibiotic usage, facilitating targeted treatments and accelerating clinical development through collaborations worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infectious Enteritis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infectious Enteritis Treatment Market Segments Analysis

Global infectious enteritis treatment market is segmented by treatment type, pathogen type, drug class, route of administration, end user, patient group and region. Based on treatment type, the market is segmented into antibacterial therapy, antiviral therapy, antiparasitic therapy, oral rehydration therapy and supportive care. Based on pathogen type, the market is segmented into bacterial enteritis, viral enteritis and parasitic enteritis. Based on drug class, the market is segmented into antibiotics, antivirals, antiparasitic agents, antidiarrheal agents, probiotics and others. Based on route of administration, the market is segmented into oral and intravenous. Based on end user, the market is segmented into hospitals, clinics, ambulatory care centers and homecare settings. Based on patient group, the market is segmented into pediatric, adult and geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infectious Enteritis Treatment Market

The Global Infectious Enteritis Treatment market is significantly driven by the emergence of rapid point-of-care diagnostic kits, which empower clinicians to efficiently identify cases of infectious enteritis and promptly commence targeted therapy. This advancement leads to reduced disease progression, shortened hospital stays, and overall improved patient outcomes, encouraging healthcare providers to widely embrace these innovative tools. Additionally, these diagnostic solutions facilitate outpatient care, expanding the market potential for medications that can be administered immediately post-diagnosis. As bedside testing becomes more accessible, it will stimulate demand across various care settings and foster collaboration between diagnostic firms and pharmaceutical companies to create integrated treatment pathways.

Restraints in the Global Infectious Enteritis Treatment Market

The Global Infectious Enteritis Treatment market faces significant challenges due to strict regulatory requirements that mandate rigorous proof of safety and efficacy for new therapeutics, which can lengthen development timelines and raise financial risks for sponsors. The necessity for comprehensive clinical trials, often required for diverse patient populations and intricate endpoints, may delay product approvals and restrict market access. Consequently, manufacturers might prefer to pursue indications with clearer regulatory routes, thereby hindering the introduction of innovative treatments for enteritis and stifling overall market expansion. Additionally, evolving international standards can result in multiple submissions across various regions, further escalating costs and deterring investments in specialized therapeutic areas.

Market Trends of the Global Infectious Enteritis Treatment Market

The Global Infectious Enteritis Treatment market is experiencing a significant shift towards precision microbiome therapeutics, driven by advancements in microbiome science. This innovative approach focuses on targeting specific pathogenic bacterial strains responsible for enteritis, utilizing comprehensive gut flora sequencing to formulate personalized probiotic and bacteriophage treatments. By selectively eliminating harmful organisms while preserving beneficial gut bacteria, these therapies enhance treatment efficacy and reduce recurrence rates, promoting overall gut health. This trend is poised to redefine the treatment landscape, offering tailored solutions for both acute and chronic enteric infections, thereby establishing a new standard based on clinically validated protocols.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Disease Epidemiology

Global Infectious Enteritis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Antibacterial Therapy
• Antiviral Therapy
• Antiparasitic Therapy
• Oral Rehydration Therapy
• Supportive Care

Global Infectious Enteritis Treatment Market Size by Pathogen Type & CAGR (2026-2033)

• Market Overview
• Bacterial Enteritis
• Viral Enteritis
• Parasitic Enteritis

Global Infectious Enteritis Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antibiotics
• Antivirals
• Antiparasitic Agents
• Antidiarrheal Agents
• Probiotics
• Others

Global Infectious Enteritis Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous

Global Infectious Enteritis Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Ambulatory Care Centers
• Homecare Settings

Global Infectious Enteritis Treatment Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Infectious Enteritis Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Pathogen Type, Drug Class, Route of Administration, End User, Patient Group)
  • US
  • Canada
• Europe (Treatment Type, Pathogen Type, Drug Class, Route of Administration, End User, Patient Group)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Pathogen Type, Drug Class, Route of Administration, End User, Patient Group)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Pathogen Type, Drug Class, Route of Administration, End User, Patient Group)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Pathogen Type, Drug Class, Route of Administration, End User, Patient Group)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norgine B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cosmo Pharmaceuticals N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RedHill Biopharma Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocodex S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations